Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial (vol 11,182,2024)

被引：0
|
作者：
Alejandri, Luis Ricardo Balleza [1 ]
Paez, Fernando Grover [1 ,2 ]
Campos, Erick Gonzalez [1 ]
Becerra, Carlos G. Ramos [1 ,2 ]
Munoz, Ernesto German Cardona [1 ,2 ]
Gonzalez, Sara Pascoe [1 ,2 ]
Zavala, Maria Guadalupe Ramos [1 ,2 ]
Roa, Africa Samantha Reynoso [1 ,2 ]
Rico, Daniel Osmar Suarez [1 ]
Ramirez, Alberto Beltran [1 ]
Galindo, Jesus Jonathan Garcia [1 ]
Mueller, David Cardona [1 ,2 ]
Ruiz, Claudia Yanette Galan [1 ,2 ]
机构：
[1] Univ Guadalajara, Univ Hlth Sci Ctr, Dept Physiol, Guadalajara 44340, Mexico
[2] Univ Guadalajara, Univ Hlth Sci Ctr, Expt & Clin Therapeut Inst, Dept Physiol,Arterial Stiffness Lab, Guadalajara 44340, Mexico
来源：
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE | 2024年 / 11卷 / 10期
关键词：
D O I：
10.3390/jcdd11100314
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial
    Jürgen H. Prochaska
    Claus Jünger
    Andreas Schulz
    Natalie Arnold
    Felix Müller
    Marc William Heidorn
    Rieke Baumkötter
    Daniela Zahn
    Thomas Koeck
    Sven-Oliver Tröbs
    Karl J. Lackner
    Andreas Daiber
    Harald Binder
    Sanjiv J. Shah
    Tommaso Gori
    Thomas Münzel
    Philipp S. Wild
    Clinical Research in Cardiology, 2023, 112 : 911 - 922
  • [32] The Effect of Iranian Propolis on Glucose Metabolism, Lipid Profile, Insulin Resistance, Renal Function and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Clinical Trial
    Mehrnoosh Zakerkish
    Maryam Jenabi
    Narjes Zaeemzadeh
    Ali Asghar Hemmati
    Niloofar Neisi
    Scientific Reports, 9
  • [33] The Effect of Iranian Propolis on Glucose Metabolism, Lipid Profile, Insulin Resistance, Renal Function and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Clinical Trial
    Zakerkish, Mehrnoosh
    Jenabi, Maryam
    Zaeemzadeh, Narjes
    Hemmati, Ali Asghar
    Neisi, Niloofar
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [34] Morus Alba leaf extract affects metabolic profiles, biomarkers inflammation and oxidative stress in patients with type 2 diabetes mellitus: A double-blind clinical trial
    Taghizadeh, Mohsen
    Zadeh, Azam Mohammad
    Asemi, Zatollah
    Farrokhnezhad, Amir Hosein
    Memarzadeh, Mohammad Reza
    Banikazemi, Zarin
    Shariat, Mohammad
    Shafabakhsh, Rana
    CLINICAL NUTRITION ESPEN, 2022, 49 : 68 - 73
  • [35] Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial
    Derosa, Giuseppe
    Cicero, Arrigo F. G.
    D'Angelo, Angela
    Fogari, Elena
    Salvadeo, Sibilla
    Gravina, Alessia
    Ferrari, Ilaria
    Fassi, Raffaella
    Fogari, Roberto
    CLINICAL THERAPEUTICS, 2007, 29 (04) : 602 - 610
  • [36] Comment on 'Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised controlled VaSera trial' by Faconti et al.
    Guimaraes, Danielle Aparecida
    Tanus-Santos, Jose Eduardo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (05) : 1035 - 1036
  • [37] Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial
    Amadi, Peter U.
    Osuoha, Justice O.
    Ekweogu, Chidi N.
    Jarad, Suha J.
    Efiong, Esienanwan E.
    Odika, Prince C.
    Ejiofor, Chioma
    Aloy-Amadi, Oluchi
    Gill, Govind S.
    Adumekwe, Chiamaka W.
    Gaowa, Ailun
    Zhang, Dawei
    de Courten, Barbora
    Agomuo, Emmanuel N.
    PHARMACOLOGICAL RESEARCH, 2025, 212
  • [38] Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial
    Prochaska, Jurgen H.
    Junger, Claus
    Schulz, Andreas
    Arnold, Natalie
    Muller, Felix
    Heidorn, Marc William
    Baumkotter, Rieke
    Zahn, Daniela
    Koeck, Thomas
    Trobs, Sven-Oliver
    Lackner, Karl J.
    Daiber, Andreas
    Binder, Harald
    Shah, Sanjiv J.
    Gori, Tommaso
    Muenzel, Thomas
    Wild, Philipp S.
    CLINICAL RESEARCH IN CARDIOLOGY, 2023, 112 (07) : 911 - 922
  • [39] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial (vol 11, pg 193, 2013)
    Bailey, Clifford J.
    Gross, Jorge L.
    Hennicken, Delphine
    Iqbal, Nayyar
    Mansfield, Traci A.
    List, James F.
    BMC MEDICINE, 2013, 11
  • [40] Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Chehrehgosha, Haleh
    Sohrabi, Masoud Reza
    Ismail-Beigi, Faramarz
    Malek, Mojtaba
    Babaei, Mohammad Reza
    Zamani, Farhad
    Ajdarkosh, Hossein
    Khoonsari, Mahmood
    Fallah, Afshin Eshghi
    Khamseh, Mohammad E.
    DIABETES THERAPY, 2021, 12 (03) : 843 - 861
12345